The argument is real, the distinction is real, and almost nobody selling oral BPC-157 tells you which one they are selling.
32 of the sellers we track list BPC-157 in capsule or tablet form, across 48 listings. 4 of those listings name the arginate salt. 0 name the acetate. The other 44 say nothing about the form at all.1
So the forum argument runs on a distinction that 28 of 32 sellers do not disclose. Before deciding which salt you want, you would have to find a seller who says.
The claim that arginate survives the stomach better comes from a patent. It sits oddly beside the research that made BPC-157 famous, because that research is built on the opposite claim. When the FDA assessed this compound in 2026, it could not tell which form had been nominated to it either.4
What is the difference between arginate and acetate?
The salt it is paired with. Nothing about the molecule itself changes. A peptide is usually sold as a salt, because the free peptide is harder to handle and store.
Acetate is the standard. It is what comes off the end of most peptide synthesis, it is what the overwhelming majority of research peptides are, and it is the form used in essentially all the published BPC-157 animal work.
Arginate pairs the peptide with arginine, a basic amino acid. The claim is that this buffers the peptide through the acid of the stomach. That would matter for a capsule and not at all for an injection.
Both are the same 15 amino acids. The salt changes handling and possibly survival in the gut, not what the molecule does once it is in you.
Where does the arginate claim come from?
A single patent, granted in 2017 to a company in Slovenia.
US patent 9,850,282, granted in 2017 to Diagen d.o.o. of Slovenia, covers salts of BPC-157 with basic amino acids: arginine, lysine or ornithine, at one, two or three molecules of amino acid per molecule of peptide.2 Its technical problem section states that the peptide had been used in free form, as an acetate, or as a sodium salt, and that all of those forms had "still not adequate stability in gastric juice". That is the sentence the whole arginate argument rests on.
Two details in the patent are not obvious from the claim built on it.
The inventor is named Rudolf Rucman, and he is a co-author on the research that made BPC-157 famous. Rucman appears on the 1993 paper describing a new gastric juice peptide, on Sikiric's 2013 colitis work, and on the 2018 review that sets out BPC-157 as a cytoprotective mediator.3 The patent arguing that existing forms are not stable enough is not from an unrelated party.
It is also the second such patent. An earlier one, US 6,288,028, granted in 2001, covered a different set of BPC salts and argued they showed remarkably increased stability compared with the free peptide or its acetate. The 2017 patent describes those earlier salts as only slightly better than the original form. Each generation argues the previous one was not stable enough.
The awkward part is the comparison. The same body of work calls BPC-157 the stable gastric pentadecapeptide. Stability in human gastric juice for more than 24 hours is its defining and most-cited property, stated in review after review, and it is the reason anyone believes an oral peptide could work at all.3
Both cannot be the headline. Either BPC-157 is remarkable for surviving the stomach, the claim that sells the whole category, or it needs a patented salt to survive the stomach, the claim that sells the capsules. The two arguments are usually made to the same buyer on the same page.
What did the FDA say about oral BPC-157?
A great deal, and it looked at the acetate rather than the arginate.
In May 2026 the FDA published a briefing document for its Pharmacy Compounding Advisory Committee, evaluating whether BPC-157 should go on the 503A bulk drug substances list. It is the most detailed assessment of this compound by anyone who is not selling it, and four things in it bear directly on the capsule question.4
The forms FDA evaluated were the free base and the acetate. Not the arginate. The document states that FDA "evaluated BPC-157 (free base) and BPC-157 acetate for the treatment of ulcerative colitis (UC)", and that the evaluation criteria "weigh against placing both" on the list.4 The salt that reached a federal evaluation is the one the forum argument calls a waste of money, and the indication was a gut disease.
The disclosure problem runs all the way up. This page opens with the finding that 28 of 32 sellers do not say which salt they are selling. FDA records the same confusion two levels higher. It notes that "it is unclear whether the nominators intended to nominate BPC-157 acetate or BPC-157 (free base)", treats the two as "different active pharmaceutical ingredients" and therefore as separate substances, and observes that clinical articles "do not always clearly identify BPC-157 as a free base or salt."4 The people who petitioned the agency did not specify the form, and neither does much of the literature.
Then the part that settles this page's central question:
- Nobody has measured absorption, by any route. FDA states it "found no human pharmacokinetic data for BPC-157 after oral, SC, nasal, or transdermal" administration.4 Not just oral. Subcutaneous injection has no human pharmacokinetic data either.
- One mucosal route has been looked at and nothing systemic appeared. FDA writes that "it does not appear that BPC-157 is absorbed systemically when given as a rectal enema."4 A rectal enema is not a capsule, but it is a mucosal route in the same tract, and it did not produce systemic exposure.
- FDA records the gastric stability claim with a qualifier the marketing drops. It notes BPC-157 was "reported to be resistant to hydrolysis in gastric juice in vitro."4 In vitro means in a test tube of gastric juice, not in a person who swallowed a capsule.
- One point in oral's favour, from the regulator. On immunogenicity, FDA writes that "in general, SC and nasal ROA is associated with increased immunogenicity compared to oral or rectal ROA", and that the "inherent immunogenic risk for BPC-157 administered orally is likely to be low."4 That is the strongest thing any official document says for the oral route, and it is about safety rather than effect.
Read together, the FDA document is harder on the systemic case than any seller page and gentler on the oral route's safety than most critics. It also leaves the gut-local case standing, since that is the indication it evaluated. None of which amounts to approval: the assessment weighs against listing either form for compounding, and our news coverage of that committee has the current state of play.
What does this mean if you are buying it?
Three things. Only the first is something you can act on.
You usually cannot tell what you are buying. Of 32 sellers listing oral BPC-157, 4 name a salt form. If the form matters to you, the practical question is not which salt but whether the seller says, and most do not.
Neither form has human evidence for oral use. No published trial establishes the effectiveness of oral BPC-157 in any salt. The arginate claim is a stability argument from a patent, not an outcome from a trial, and our guide on whether peptide capsules work covers how rarely stability translates into absorption.
The animal work that convinces people is not oral capsule work. Much of the rat research gave BPC-157 in drinking water. That is oral, and it is also a very different thing from a capsule in a human stomach: different dose, different species, different gastric chemistry, no attempt to measure how much reached the blood.
Does oral BPC-157 work for the gut and for tendons?
Two different answers, depending on the target. Absorption decides one of them and is irrelevant to the other.
If you want it to act on the gut, absorption is not the obstacle, it is beside the point. A capsule puts the peptide directly onto the lining of the stomach and intestine. For stomach or bowel complaints, nothing needs to cross into the blood for the peptide to be where you wanted it. The salt argument matters here, because surviving stomach acid is how it reaches the intestine intact. This is also the version a regulator has taken seriously enough to assess: the indication in the FDA's evaluation was ulcerative colitis.4
If you want it to act on a tendon, a joint or anything else, absorption is the entire question. The peptide has to cross the gut wall, survive the liver and arrive somewhere else in sufficient quantity. Oral bioavailability for BPC-157 in humans has never been measured, in either salt, and the FDA found no human pharmacokinetic data for any route.4
People asking about gut healing and people asking about a shoulder are asking different questions and treating the answers as interchangeable.
It is also the sharper version of the stability claim. A salt that survives the stomach better gets more peptide into the intestine. Whether more peptide in the intestine means more peptide in your bloodstream is a second step that nothing in the patent addresses.
What did the oral animal studies actually test?
They gave the peptide in drinking water to rats and measured what happened in gut tissue.
Much of the oral BPC-157 research gave the peptide in drinking water to rats, and much of it measured effects on the gut: ulcers, bowel injury, damage from anti-inflammatory drugs. Those are the studies where the oral route and the target sit in the same place.
Three differences from a capsule in a person. The doses in rodent studies cannot be directly compared with a human capsule. Rat gastric chemistry is not human gastric chemistry. And those studies generally measured an outcome in the tissue rather than a concentration in the blood, so they establish that something happened locally, not that the peptide was absorbed.
None of that makes the research worthless. It is evidence for a specific claim: that oral BPC-157 can act on a rat's gut. It is not evidence that a capsule heals a human tendon, the claim people usually want.
Is oral BPC-157 cheaper than injecting it?
Per milligram, yes: the oral median is 44% lower. Most people assume the opposite.
Across the oral listings that state both a capsule strength and a count, the median works out at $3.35 per mg of BPC-157. The median injectable vial runs $6.00 per mg.1
| Median | Typical presentation | |
|---|---|---|
| Oral capsules and tablets | $3.35 per mg | 500 mcg per capsule, 30 to 100 per bottle |
| Injectable vials | $6.00 per mg | 5 or 10 mg per vial |
That comparison is not the bargain it looks like. Price per milligram is only meaningful if the milligrams arrive, and for a peptide swallowed whole that is exactly what is unknown. Paying 44% less per mg for a route that delivers an unknown and probably small fraction is not a saving, it is a different purchase.
28 oral listings lack unambiguous single-compound total content or are blends, so they are excluded from the oral median. That is its own answer about disclosure in this market.
Why does the argument never resolve?
Three confident positions circulate, all arguing from the same thin evidence.
One says oral BPC-157 is pointless because peptides are destroyed in the stomach. One says BPC-157 is the exception because it came from gastric juice. One says only the arginate salt works orally and the acetate is a waste of money.
All three are arguing from the same thin evidence base. The first is right about peptides generally. The second is right that BPC-157's gastric stability is unusual and well documented. The third is restating a patent.
What none of them has is a measurement of how much BPC-157, in either salt, reaches the bloodstream of a human being after a capsule. That study does not exist. Until it does, the argument is about mechanism and the answer is unknown.
What should you ask a seller?
Four questions. The first two are the ones that get vague answers.
Which salt is it, and does the certificate of analysis name the salt form? A COA for the peptide does not establish which salt was used unless it says so.
What is the stated content per capsule, and is that peptide content or total salt weight? That one has an arithmetic answer.
BPC-157 itself weighs 1,419 daltons. Arginine adds 174 per molecule, and the patent allows one, two or three of them, with its worked examples for lysine and ornithine using two.2 So an arginate salt is roughly 89% peptide by weight at one arginine, 80% at two and 73% at three. An acetate salt is about 96% peptide.
A 500 mcg capsule of a two-to-one arginate therefore carries around 400 mcg of actual peptide, against about 480 mcg for the same stated weight of acetate. That is a difference of roughly a sixth, in the opposite direction to the price. Almost no seller states which ratio they are selling, so this is a question to ask rather than a calculation you can do from a listing.
Our guide on reading a COA covers what the document can and cannot establish.
Common questions
Is arginate BPC-157 better than acetate?
For oral use the claim is that arginate survives stomach acid better, and it comes from a patent covering salts of BPC-157 with basic amino acids. No trial has compared the two in humans, in either form, by any measure of absorption or outcome.
Does oral BPC-157 work?
Nobody has measured how much reaches the bloodstream from a capsule in a human. The FDA's 2026 briefing document states it found no human pharmacokinetic data for BPC-157 after oral, subcutaneous, nasal or transdermal administration, so the gap covers injection too. The animal work that convinces people mostly used drinking water in rats, not capsules in people.
How can I tell which salt I am buying?
Usually you cannot. Of 32 sellers we track listing oral BPC-157, 4 name the arginate salt and 0 name the acetate across 0 listings. The other 28 do not say.
Is oral cheaper than injectable?
Per milligram, yes: a median of $3.35 against $6.00 for vials. That only matters if the milligrams are absorbed, and absorption is the unanswered question.
If BPC-157 is stable in gastric juice, why does it need a special salt?
That tension is real and sits inside the same body of work. The compound is known as the stable gastric pentadecapeptide for surviving human gastric juice, and the patent for the arginate salt argues existing forms are not stable enough in gastric juice for oral use.
Does oral BPC-157 work for gut problems?
That is the version of the question with the most behind it. A capsule puts the peptide directly onto the gut lining, so absorption into the blood is not required for it to reach the target, and most of the oral animal research measured gut outcomes. Whether it does anything for a human gut has not been tested in a trial.
Does oral BPC-157 work for tendons or joints?
That requires absorption into the blood. Nobody has measured it in a human in either salt form. The oral animal studies mostly gave the peptide in drinking water and measured effects in the gut, not concentrations in the bloodstream.
Does the salt change what the peptide does?
No. Both are the same 15 amino acids. The salt affects handling, storage and possibly survival in the gut, not the molecule's activity once absorbed.
Does a 500 mcg capsule contain 500 mcg of peptide?
Not necessarily. BPC-157 weighs 1,419 daltons and each arginine adds 174, with the patent allowing one to three per peptide molecule. That makes an arginate roughly 73 to 89% peptide by weight against about 96% for an acetate, so a 500 mcg arginate capsule may carry around 400 mcg of peptide. Sellers rarely state the ratio.
What did the FDA say about BPC-157?
It evaluated the compound for ulcerative colitis and its assessment weighed against allowing it to be compounded. The May 2026 briefing document for the Pharmacy Compounding Advisory Committee states that FDA found no human pharmacokinetic data for BPC-157 after oral, subcutaneous, nasal or transdermal administration, that BPC-157 does not appear to be absorbed systemically when given as a rectal enema, and that the compound was reported to be resistant to hydrolysis in gastric juice in vitro. Committee recommendations are not binding and BPC-157 is not on the 503A bulks list.
Which salt form of BPC-157 did the FDA evaluate?
The free base and the acetate, as two separate substances. The arginate was not nominated. The document also notes that it was unclear which of the two the nominators meant, that the free base and the acetate are different active pharmaceutical ingredients, and that clinical articles do not always identify which one they used.
Is oral BPC-157 safer than injecting it?
On one measure, the FDA document leans that way. It states that subcutaneous and nasal routes are generally associated with increased immunogenicity compared with oral or rectal routes, and that the inherent immunogenic risk of BPC-157 given orally is likely to be low. That is a statement about immune reaction rather than about whether the oral route does anything, and the same document raises other peptide-related concerns and weighs against compounding either form.
What about sublingual BPC-157?
A different route again, and a thinner one. Sublingual products aim to absorb under the tongue and bypass the stomach entirely. That makes the salt argument irrelevant and the absorption question harder, since the area under the tongue is small and a 15 amino acid peptide is large. No human study measures it.
Is oral BPC-157 worth it?
That depends on the target rather than the price. For a gut complaint, a capsule puts the peptide where you want it without needing absorption. For anything systemic, you are paying for milligrams whose bioavailability nobody has measured.
Should I buy the arginate then?
Our site does not make that recommendation. What we can say is that 4 sellers disclose the form, no human study supports either, and the price difference per milligram runs the opposite way to what most people assume.
Sources
- Peptide Decoding vendor price capture, 11 October 2026. peptidedecoding.com/prices. Our own data, counting one priced product at one seller as a listing. BPC-157 appears in 401 listings across 137 sellers. 48 of those listings, from 32 sellers, are capsules or tablets; 4 listings from 4 sellers name the arginate salt and 0 listings from 0 sellers name the acetate. Among single-compound oral listings stating both a per-unit strength and a count, the median works out at $3.35 per mg across 20 listings from 13 sellers; 28 oral listings lack unambiguous single-compound total content or are blends. In-stock single injectable vials priced in milligrams run a median of $6.00 per mg across 166 listings.
- Stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy. US patent 9,850,282. patft.uspto.gov. The patent covering salts of BPC-157 with basic amino acids. Its technical problem section states that the peptide had until then been used in free form, in an acetate form, or as a salt with bases such as the sodium salt, and that all these forms were characterised by still not adequate stability in gastric juice, which particularly limits oral use and decreases therapeutic value. Read as the origin of the arginate stability claim rather than as independent evidence for it.
- Sikiric P, Rucman R, Turkovic B, et al. Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing. Current Pharmaceutical Design 2018;24(18):1990-2001. PMID 29879879. One of the review papers from the group that discovered BPC-157, describing it as native and stable in human gastric juice for more than 24 hours, which is the basis of the stable gastric pentadecapeptide name. Rudolf Rucman, the named inventor on US patent 9,850,282, is a co-author here and on the 1993 paper first describing the peptide in gastric juice, and on Sikiric et al., FASEB Journal 2013, on colitis.
- FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of 23-24 July 2026, memo dated 11 May 2026. US Food and Drug Administration. fda.gov/media/193343/download. Read at source. Covers BPC-157 (free base) and BPC-157 acetate as separate nominated substances, plus two withdrawn nominations. States that FDA "evaluated BPC-157 (free base) and BPC-157 acetate for the treatment of ulcerative colitis (UC)" and, in its introduction, that "the evaluation criteria weigh against placing both BPC-157 (free base) and BPC-157 acetate" on the list of bulk drug substances that can be used in compounding. On the forms: "it is unclear whether the nominators intended to nominate BPC-157 acetate or BPC-157 (free base)", the two are "different active pharmaceutical ingredients", and clinical articles "do not always clearly identify BPC-157 as a free base or salt". On pharmacokinetics: "We found no human pharmacokinetic data for BPC-157 after oral, SC, nasal, or transdermal" administration, and "it does not appear that BPC-157 is absorbed systemically when given as a rectal enema". Notes BPC-157 was "reported to be resistant to hydrolysis in gastric juice in vitro". On immunogenicity: "In general, SC and nasal ROA is associated with increased immunogenicity compared to oral or rectal ROA", and the "inherent immunogenic risk for BPC-157 administered orally is likely to be low", alongside other peptide-related concerns. The Conclusion and Recommendation section sat beyond the retrieved portion of the document, so the final recommendation wording is not quoted and the introduction's framing is used instead. The arginate salt is not among the nominated substances.
Citing this page. Peptide Decoding. Oral BPC-157: Arginate vs Acetate, and Why Most Sellers Will Not Say. Regulatory assessment from the FDA Pharmacy Compounding Advisory Committee briefing document of 11 May 2026; patent text from US 9,850,282; listing data from the 11 October 2026 capture. https://peptidedecoding.com/guides/oral-bpc-157-salt-forms